Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosis

Reuters2026/08/06 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Roivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a condition with no approved therapies.
Results will be presented in the future, with BEACON+ topline data expected in 2028.
The study follows a positive Phase 2 outcome that supported FDA Breakthrough Therapy Designation, positioning brepocitinib as a potential new treatment option.
Priovant expects a U.S. regulatory decision in dermatomyositis by end-September 2026, supporting a near-term launch path for the drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosis

You may also like

Crypto prices